Search Results - "Abbas, Gulam"

Current and Emerging Therapies in Metastatic Pancreatic Cancer by Manji, Gulam Abbas, Olive, Kenneth P, Saenger, Yvonne M, Oberstein, Paul

“…Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies…”
Get full text

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial by Zhu, Andrew X, Finn, Richard S, Edeline, Julien, Cattan, Stephane, Ogasawara, Sadahisa, Palmer, Daniel, Verslype, Chris, Zagonel, Vittorina, Fartoux, Laetitia, Vogel, Arndt, Sarker, Debashis, Verset, Gontran, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Webber, Andrea L, Ebbinghaus, Scot W, Ma, Junshui, Siegel, Abby B, Cheng, Ann-Lii, Kudo, Masatoshi, Alistar, Angela, Asselah, Jamil, Blanc, Jean-Frederic, Borbath, Ivan, Cannon, Timothy, Chung, Ki, Cohn, Allen, Cosgrove, David P, Damjanov, Nevena, Gupta, Mukul, Karino, Yoshivasu, Karwal, Mark, Kaubisch, Andreas, Kelley, Robin, Van Laethem, Jena-Luc, Larson, Timothy, Lee, James, Li, Daneng, Manhas, Atisha, Manji, Gulam Abbas, Numata, Kazushi, Parsons, Benjamin, Paulson, Andrew S., Pinto, Carmine, Ramirez, Robert, Ratnam, Suresh, Rizell, Magnus, Rosmorduc, Olivier, Sada, Yvonne, Sasaki, Yutaka, Stal, Per I, Strasser, Simone, Trojan, Joerg, Vaccaro, Gina, Van Vlierberghe, Hans, Weiss, Alan, Weiss, Karl-Heinz, Yamashita, Tatsuya

“…Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety…”
Get full text

Retraction of “Effect of Reaction Temperature on Shape Evolution of Palladium Nanoparticles and Their Cytotoxicity against A‑549 Lung Cancer Cells” by Abbas, Gulam, Kumar, Narinder, Kumar, Devesh, Pandey, Gajanan

“…[This retracts the article DOI: 10.1021/acsomega.9b02776.]…”
Get full text

Retraction of “One-Pot Surface Modification of β‑Cu2O NPs for Biocatalytic Performance against A‑549 Lung Carcinoma Cell Lines through Docking Analysis” by Abbas, Gulam, Pandey, Gajanan, Singh, Kijay Bahadur, Gautam, Neelam

Get full text

Effect of Reaction Temperature on Shape Evolution of Palladium Nanoparticles and Their Cytotoxicity against A‑549 Lung Cancer Cells by Abbas, Gulam, Kumar, Narinder, Kumar, Devesh, Pandey, Gajanan

“…Palladium nanoparticles (Pd NPs) of different shapes and sizes have been synthesized by reducing potassium tetrachloropalladinate(II) by l-ascorbic acid (AA)…”
Get full text

One-Pot Surface Modification of β‑Cu2O NPs for Biocatalytic Performance against A‑549 Lung Carcinoma Cell Lines through Docking Analysis by Abbas, Gulam, Pandey, Gajanan, Singh, Kijay Bahadur, Gautam, Neelam

“…The physicochemical approaches and biological principles in bio-nanotechnology favor specially functionalized nanosized particles. Cuprous oxide nanoparticles…”
Get full text

Metal organic framework supported surface modification of synthesized nickel/nickel oxide nanoparticles via controlled PEGylation for cytotoxicity profile against MCF-7 breast cancer cell lines via docking analysis by Abbas, Gulam

“…•Ni/NiO@LAA_PEG NPs are applied in various biological fields.•Nanoparticles and nanostructures are materials with dimensions at or below 100 nm and have…”
Get full text

Clinical outcome of diabetes patients hospitalized with foot ulcers, Dar es Salaam, Tanzania by Gulam-Abbas, Z., Lutale, J. K., Morbach, S., Archibald, L. K.

“…Aims To determine the prevalence rate, clinical features, risk factors, and clinical outcome of foot ulcers in diabetes patients admitted to Muhimbili National…”
Get full text

MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS -mutated advanced malignancies by Raufi, Alexander, Wong, Winston, Lee, Shing Mirn, Manji, Gulam Abbas

“…Abstract only TPS450 Background: Pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma (CRC) are aggressive diseases which account for the third and…”
Get full text

Antitumor efficacy of synthesized Ag-Au nanocomposite loaded with PEG and ascorbic acid in human lung cancer stem cells by Abbas, Gulam, Saluja, Tajindra Singh, Kumar, Dharmendra, Agrawal, Hemant, Gupta, Anurag, Panday, Gajanan, Singh, Satyendra Kumar

“…Lung cancer is the leading cause of mortality worldwide of which non-small cell lung carcinoma constitutes majority of the cases. High mortality is attributed…”
Get full text

Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania by Lutale, J J K, Thordarson, H, Gulam-Abbas, Z, Vetvik, K, Gerdts, E

“…Left ventricular hypertrophy (LVH) has been demonstrated to be a powerful predictor of cardiovascular (CV) morbidity and mortality in diabetic as well as…”
Get full text

Chemo4MetPanc: A phase II study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment naïve pancreas adenocarcinoma (PDAC) by Pellicciotta, Ilenia, Alouani, Emily Linda, Raufi, Alexander, Pan, Samuel M, Hu, Jianhua, Manji, Gulam Abbas

“…Abstract only TPS454 Background: Pancreas adenocarcinoma (PDAC) is an aggressive cancer projected to be the second leading cause of cancer-related death in the…”
Get full text

CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma by Manji, Gulam Abbas, May, Michael S., Pellicciotta, Ilenia, Sta Ana, Sarah, Sender, Naomi, Pan, Samuel M, Ross, Isabelle, Hu, Jianhua, Shi, Qian, Raufi, Alexander G

“…TPS4200 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease for which treatments result in limited benefit. Failure of…”
Get full text

Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in locally advanced/borderline resectable pancreatic cancer patients by Ingram, Myles, Lauren, Brianna N, Pumpalova, Yoanna S, Manji, Gulam Abbas, Bates, Susan Elaine, Hur, Chin

“…Abstract only e16793 Background: The 2019 NCCN guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab-paclitaxel (G-nP) for locally…”
Get full text

Morphology controlled biogenic fabrication of Metal/Metal oxide nanostructures using plant extract and their application in organic transformations by Bahadur Singh, Kijay, Gautam, Neelam, Upadhyay, D.D., Abbas, Gulam, Rizvi, Marziya, Pandey, Gajanan

“…[Display omitted] •This review article consist a concise survey for biogenic synthesis of Metal/Metal Oxide Nanostructures.•Factors influencing morphology…”
Get full text

Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer by Ingram, Myles, Pumpalova, Yoanna S, Park, Jiheum, Lim, Francesca, Manji, Gulam Abbas, Kong, Chung Yin, Hur, Chin

“…Abstract only e16246 Background: Patients with germline BRCA1/2 mutations (gBRCAm) have an increased risk for pancreatic ductal adenocarcinoma (PDAC). The NCCN…”
Get full text

CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma by Manji, Gulam Abbas, May, Michael S., Chalabi, Morteza, Pellicciotta, Ilenia, Sta Ana, Sarah, Sender, Naomi, Pan, Samuel M, Ross, Isabelle, Wang, Shikun, Izar, Benjamin, Wu, Linda, Labadie, Brian William, Bates, Susan Elaine, Shi, Qian, Raufi, Alexander G

“…TPS4208 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) carries a 5-year relative survival of 3%. Immune checkpoint inhibitors have thus far…”
Get full text

Recurrence patterns and surveillance strategies in long-term survivors of resected pancreatic cancer by May, Michael S., Stanton, Liam James, Jamison, Jacob K., May, Benjamin, Michel, Alissa M., Raufi, Alexander G., Wong, Winston, Kastrinos, Fay, Accordino, Melissa Kate, Hershman, Dawn L., Manji, Gulam Abbas, Wu, Linda

“…e16361 Background: Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related mortality in the United States. After resection, the…”
Get full text

Retraction of "One-Pot Surface Modification of β-Cu 2 O NPs for Biocatalytic Performance against A-549 Lung Carcinoma Cell Lines through Docking Analysis" by Abbas, Gulam, Pandey, Gajanan, Singh, Kijay Bahadur, Gautam, Neelam

“…[This retracts the article DOI: 10.1021/acsomega.1c02942.]…”
Get full text

AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection by Manji, Gulam Abbas, Labadie, Brian William, Jamison, Jacob K., Wu, Linda, Wang, Shikun, Pellicciotta, Ilenia, Sta Ana, Sarah, Sender, Naomi, Ross, Isabelle, Cho, Hope, Horowitz, David Paul, Chabot, John A.

“…TPS714 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which immune checkpoint blockade (ICB) has not provided benefit,…”
Get full text